PE20071139A1 - Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido - Google Patents

Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido

Info

Publication number
PE20071139A1
PE20071139A1 PE2006001665A PE2006001665A PE20071139A1 PE 20071139 A1 PE20071139 A1 PE 20071139A1 PE 2006001665 A PE2006001665 A PE 2006001665A PE 2006001665 A PE2006001665 A PE 2006001665A PE 20071139 A1 PE20071139 A1 PE 20071139A1
Authority
PE
Peru
Prior art keywords
polymers
sustained release
polylactide
release formulation
formulation including
Prior art date
Application number
PE2006001665A
Other languages
English (en)
Inventor
Holger Petersen
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20071139A1 publication Critical patent/PE20071139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION SOSTENIDA QUE COMPRENDE a) COMO INGREDIENTE ACTIVO OCTEOTRIDA O UNA SAL FARMACEUTICAMENTE ACEPTABLE SIENDO PREFERIDA LA SAL DE PAMOATO DE OCTEOTRIDA; Y b) DOS O MAS DIFERENTES POLIMEROS DE POLIACTIDO-CO-GLICOLIDO (PLGAs), PRESENTES COMO MEZCLA DE POLIMEROS, QUE TIENEN UNA RELACION DE MONOMERO DE LACTIDO:GLICOLIDO DE 100:0 A 40:6O, Y LA VISCOCIDAD INHERENTE DE LOS POLIMEROS ESTA POR ABAJO DE 0.9 DL/G EN CLOROFORMO. ESTA COMPOSICION PUEDE PRESENTARSE BAJO LA FORMA DE MICROPARTICULAS CON UN DIAMETRO ENTE 10 um A 90 um LAS CUALES SON REVESTIDAS CON UN AGENTE ANTI-AGLOMERACION, UN SEMI-SOLIDO U UN IMPLANTE, OBTENIENDOSE ASI UNA LIBERACION DEL INGREDIENTE ACTIVO DE 3 A MAS MESES
PE2006001665A 2005-12-22 2006-12-20 Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido PE20071139A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
EP06119086 2006-08-17

Publications (1)

Publication Number Publication Date
PE20071139A1 true PE20071139A1 (es) 2007-11-16

Family

ID=37772904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001665A PE20071139A1 (es) 2005-12-22 2006-12-20 Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido

Country Status (22)

Country Link
US (6) US20090004283A1 (es)
EP (3) EP1968549B1 (es)
JP (4) JP2009520727A (es)
KR (5) KR20130024988A (es)
CN (1) CN103251929A (es)
AR (1) AR058591A1 (es)
AU (1) AU2006328950B2 (es)
BR (2) BRPI0620063B8 (es)
CA (1) CA2631811C (es)
CL (1) CL2018003398A1 (es)
EC (1) ECSP088560A (es)
ES (2) ES2492641T3 (es)
IL (1) IL191842A0 (es)
IN (1) IN2015DN03936A (es)
MA (1) MA30064B1 (es)
NO (1) NO20082988L (es)
PE (1) PE20071139A1 (es)
PL (2) PL2359809T3 (es)
PT (2) PT1968549E (es)
RU (1) RU2464972C2 (es)
TW (2) TWI469788B (es)
WO (1) WO2007071395A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2164467T3 (en) 2007-06-06 2017-01-30 Debiopharm Res & Mfg Sa Slow release pharmaceutical composition consisting of microparticles
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
KR20100110848A (ko) * 2008-01-30 2010-10-13 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
US20100105627A1 (en) 2008-09-17 2010-04-29 Paul Salama Pharmaceutical compositions and related methods of delivery
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
CA2750003A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
WO2012012546A2 (en) * 2010-07-21 2012-01-26 Allergan, Inc. METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
RU2586306C2 (ru) 2011-04-25 2016-06-10 Шандонг Люие Фармацеутикал Ко., Лтд Состав с микросферами для длительного непрерывного высвобождения рисперидона
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
EP3318174A4 (en) * 2015-06-26 2019-04-10 Olympus Corporation ENDOSCOPE POWER SUPPLY SYSTEM
US20220000782A1 (en) * 2016-12-27 2022-01-06 Upexmed Co. Ltd. Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
JP6810502B1 (ja) * 2020-05-08 2021-01-06 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
JP6852943B1 (ja) * 2020-05-08 2021-03-31 エム・テクニック株式会社 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
KR20220163418A (ko) * 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0029579B1 (en) * 1979-11-27 1983-02-16 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
ZA9711385B (en) * 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
CA2291659A1 (fr) * 1997-06-04 1998-12-10 Debio Recherche Pharmaceutique S.A. Implants pour la liberation controlee de principes pharmaceutiquement actifs et procede pour leur fabrication
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1344520B1 (en) * 2002-03-15 2007-10-03 Alrise Biosystems GmbH Microparticles and method for their production
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
CA2915574C (en) * 2003-07-18 2017-02-07 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
PL1786400T3 (pl) * 2004-08-12 2009-08-31 Quest Pharmaceutical Services Kompozycje farmaceutyczne do dostarczania biologicznie czynnych związków metodą kontrolowanego uwalniania

Also Published As

Publication number Publication date
AR058591A1 (es) 2008-02-13
JP2015044823A (ja) 2015-03-12
BRPI0620063A8 (pt) 2018-05-02
EP1968549B1 (en) 2014-05-14
JP2016216467A (ja) 2016-12-22
US20090004283A1 (en) 2009-01-01
ECSP088560A (es) 2008-07-30
EP3603623A1 (en) 2020-02-05
ES2755032T3 (es) 2020-04-21
ES2492641T3 (es) 2014-09-10
JP6178772B2 (ja) 2017-08-09
AU2006328950A1 (en) 2007-06-28
CL2018003398A1 (es) 2019-04-26
EP1968549A1 (en) 2008-09-17
AU2006328950B2 (en) 2010-07-29
PT1968549E (pt) 2014-08-29
KR20080078000A (ko) 2008-08-26
RU2008129626A (ru) 2010-01-27
TW200803921A (en) 2008-01-16
JP6239851B2 (ja) 2017-11-29
EP2359809B1 (en) 2019-08-14
US20200206306A1 (en) 2020-07-02
KR20130024987A (ko) 2013-03-08
IN2015DN03936A (es) 2015-10-02
TWI469788B (zh) 2015-01-21
KR20130024986A (ko) 2013-03-08
WO2007071395A1 (en) 2007-06-28
JP2009520727A (ja) 2009-05-28
KR20130024988A (ko) 2013-03-08
NO20082988L (no) 2008-08-29
EP2359809A1 (en) 2011-08-24
BRPI0620063B8 (pt) 2021-05-25
US20160120935A1 (en) 2016-05-05
BR122019027412B8 (pt) 2021-07-27
CA2631811A1 (en) 2007-06-28
BR122019027412B1 (pt) 2020-12-01
IL191842A0 (en) 2008-12-29
TW201424747A (zh) 2014-07-01
MA30064B1 (fr) 2008-12-01
US20220296675A1 (en) 2022-09-22
JP2013177406A (ja) 2013-09-09
TWI468172B (zh) 2015-01-11
BRPI0620063A2 (pt) 2011-11-01
KR101458728B1 (ko) 2014-11-05
RU2464972C2 (ru) 2012-10-27
PT2359809T (pt) 2019-11-04
BRPI0620063B1 (pt) 2020-09-08
CN103251929A (zh) 2013-08-21
PL1968549T3 (pl) 2014-10-31
US20180140662A1 (en) 2018-05-24
US20150037420A1 (en) 2015-02-05
PL2359809T3 (pl) 2020-01-31
KR101245919B1 (ko) 2013-03-20
CA2631811C (en) 2017-06-20
KR20140133968A (ko) 2014-11-20

Similar Documents

Publication Publication Date Title
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
KR102536696B1 (ko) 향상된 투과성을 가지는 약물학적 조성물
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
JP2023052143A (ja) 送達増強エピネフリン組成物
PE20081297A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR052153A1 (es) Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
WO2005009357A3 (en) Controlled release compositions
CA2468703A1 (en) Controlled release polymeric compositions of bone growth promoting compounds
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
NZ604997A (en) Sustained release formulations using non-aqueous carriers
JP7431724B2 (ja) 増強された透過を有する医薬組成物
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
ATE476997T1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
CO5060477A1 (es) Forma de dosificacion de nefazodona
RU2006147244A (ru) Способ составления быстро диспергируемых лекарственных форм, содержащих по меньшей мере один рыбий желатин, который выбирают на основе молекулярной массы
AR072668A1 (es) Encapsulacion de agentes biologicamente activos
JP2020535162A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物

Legal Events

Date Code Title Description
FC Refusal